# Study of SHR-1209 in the Treatment of Hypercholesterolemia and Hyperlipidemia Ⅲ Stage

> **NCT04849000** · PHASE3 · COMPLETED · sponsor: **Jiangsu HengRui Medicine Co., Ltd.** · enrollment: 709 (actual)

## Conditions studied

- Primary Hypercholesterolemia
- Mixed Hyperlipemia

## Interventions

- **DRUG:** SHR-1209
- **DRUG:** SHR-1209 Placebo

## Key facts

- **NCT ID:** NCT04849000
- **Lead sponsor:** Jiangsu HengRui Medicine Co., Ltd.
- **Sponsor class:** INDUSTRY
- **Phase:** PHASE3
- **Study type:** INTERVENTIONAL
- **Status:** COMPLETED
- **Start date:** 2021-04-23
- **Primary completion:** 2022-06-21
- **Final completion:** 2023-01-13
- **Target enrollment:** 709 (ACTUAL)
- **Last updated:** 2023-05-19


## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT04849000

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT04849000, "Study of SHR-1209 in the Treatment of Hypercholesterolemia and Hyperlipidemia Ⅲ Stage". Retrieved via AI Analytics 2026-05-28 from https://api.ai-analytics.org/clinical/NCT04849000. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*